Who will it be?
It seems like a matter of time before Tandem is acquired. The stock is sinking into the abyss, the Board seems content to do nothing and they are sitting on a boatload of cash. As we have noted before this is not like the last time the company was on the verge of collapse. Thankfully today besides sitting on over $500 million in cash they have an installed base of over 430,000 patients. In other words, there is something to buy here other than hope.
The question is who will make the deep dive. Will it be Dexcom? Will . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.